as 10-24-2025 3:56pm EST
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 60.3M | IPO Year: | N/A |
| Target Price: | $32.67 | AVG Volume (30 days): | 146.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.28 - $11.06 | Next Earning Date: | 11-12-2025 |
| Revenue: | $286,000 | Revenue Growth: | -35.29% |
| Revenue Growth (this year): | -31.2% | Revenue Growth (next year): | 1363.77% |
CLNN Breaking Stock News: Dive into CLNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
GlobeNewswire
5 days ago
GlobeNewswire
10 days ago
ACCESS Newswire
4 months ago
Simply Wall St.
4 months ago
ACCESS Newswire
5 months ago
GlobeNewswire
5 months ago
GlobeNewswire
6 months ago
The information presented on this page, "CLNN Clene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.